Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme
versus placebo in patients with malignant pleural mesothelioma. Malignant pleural
mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that
by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve
and die.